Could a leukemia drug help lung cancer patients Who've run out of options?
NCT ID NCT07140016
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 39 times
Summary
This early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with advanced ALK-positive non-small cell lung cancer whose cancer has stopped responding to standard ALK inhibitors. The main goal is to check the drug's safety and tolerability. Participants take gilteritinib tablets daily and are monitored for up to 4 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
OSF Health Care
RECRUITINGPeoria, Illinois, 61637, United States
-
Site ES34006
RECRUITINGMadrid, Spain
-
Site ES34008
RECRUITINGMálaga, Spain
-
Site ES34011
RECRUITINGMadrid, Spain
-
Site ES34017
RECRUITINGBarcelona, Spain
-
Site FR33001
RECRUITINGVillejuif, France
-
Site FR33005
RECRUITINGToulouse, France
-
Site FR33008
RECRUITINGSaint-Herblain, France
-
UT Southwestern Medical Center at Dallas
RECRUITINGDallas, Texas, 75390, United States
-
University of California - Irvine
RECRUITINGOrange, California, 92868, United States
-
University of Michigan Health Systems
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Virginia Cancer Specialists PC
RECRUITINGFairfax, Virginia, 22031, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.